Some studies have found a link between intestinal microbiota composition and development of acute graft-versus-host disease.
Haploidentical related donor transplants may offer cost savings for patients in need of an alternative donor source for allogeneic transplant.
Busulfan usage, high ferritin levels prior to HSCT, and treatment with some antibody-drug conjugates were deemed to be risk facts for VOD/SOS.
The ASBMT released a position statement recommending autologous hematopoietic cell transplantation as treatment for relapsing multiple sclerosis.
The European Conference on Infections in Leukaemia conducted a thorough literature review to develop guidelines for safely vaccinating HSCT recipients.
Screening for pulmonary impairment following respiratory viral infection may help identify patients at high risk for transplant-related mortality.
There are currently limited data on recipients of allogeneic hematopoietic cell transplantation from alternative graft sources.
Patients with fever and neutropenia who had undergone allogeneic hematopoietic stem cell transplantation and experienced pre-engraftment bacteremia were assessed.
Patients received alemtuzumab as part of a reduced intensity condition regimen and demonstrated early immune recovery.
Cytomegalovirus infection is a common complication of allogeneic hematopoietic cell transplantation.
Oral vancomycin is effective in preventing C difficile infection in allogeneic hematopoietic cell transplant patients and does not raise the risk for GVHD.
A history of chronic graft-vs-host disease was a risk factor for the development of late-stage fatal infections.
Mortality and relapse incidence were assessed in patients with non-Hodgkin lymphoma after allogeneic hematopoietic cell transplantation (alloHCT).
Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.
In this retrospective study, researchers assessed the outcomes of 88 patients with hematologic disease who underwent HSCT.
Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.
US FDA issues a recommendation on use of azithromycin in patients with hematologic malignancies who have undergone HSCT.
Study sought to determine the health-related QOL and posttraumatic stress symptoms in adolescent and young adult cancer survivors post-HSCT compared with their healthy peers.
In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.
Researchers assessed the effectiveness of low level laser therapy in preventing or minimizing oral mucositis in patients with hematologic cancers preparing to undergo HSCT. Results were presented at the 2018 ONS Annual Congress.
Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.
Sinusoidal obstruction syndrome (or hepatic veno-occlusive disease), a complication observed in patients who undergo HSCT, is managed with defibrotide. In this study, investigators assessed its efficacy and patient response to therapy.
Patients who received a single infusion achieved a cumulative complete or partial response rate of 92%, with 100% for BKV, 100% for EBV, 94% for CMV, 71% for AdV, and 67% for HHV-6.
Patients with vitamin D deficiency had a higher risk of relapse; deficiency was also associated with a trend towards inferior survival.
Pediatric patients with hematological malignancies who receive HSCT from an unrelated donor have greater benefit from a 15 mg/kg vs a 30 mg/kg dose of ATLG.
Palliative care added to transplant care improved relief from depression and PTSD symptoms following hematopoietic stem cell transplantation.
A nurse-led team developed a tracking tool that created a vaccination schedule from transplant date forward for autologous hematopoietic stem cell transplant recipients.
An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.
The FDA accepted for review a supplemental New Drug Application for ibrutinib as a treatment for chronic graft-versus-host-disease.
The findings of this study suggest that leflunomide may be an effective treatment of CMV infection among patients who have received allo-HSCT.
A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.
An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.
Allogeneic HSCT following treatment with an anti-PD-1 monoclonal antibody appears feasible in patients with relapsed/refractory lymphoma.